Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a degenerative disease of the macula, the central part of the retina that is responsible for fine visual details. Previous classification systems referred to “wet” and “dry” manifestations of AMD. Newer terminology favors the use of “early” and “late” stages of AMD. Early AMD is characterized by the presence of small drusen, which are focal, yellow deposits in the retina. These can be visualized under dilated ophthalmologic examination. Small, infrequent deposits are virtually always found in people over age 50 and are not necessarily pathological. In conjunction with increased or decreased pigmentation in the pigmented epithelium layer of the retina, drusen are a sign of early AMD. Early AMD may be asymptomatic, or may cause blurred vision or poor vision in low light.
As AMD progresses to late stages, central vision gradually worsens until patients are no longer able to perform tasks requiring fine visual skills. AMD is the most common cause of legal blindness (20/200 or worse in both eyes) among elderly Americans. Peripheral vision is often spared until later in the disease, and if adequate, may allow limited performance of some daily activities.
The late stage is divided into neovascular AMD and nonneovascular AMD. Neovascular AMD was previously known as “wet” AMD, due to abnormal vessel growth (neovascularization) into the subretinal space. It is less common than nonneovascular AMD (10%-15% of cases), but has a worse prognosis and accounts for most cases of extensive vision loss. Because it can progress quickly, any sudden changes in vision should prompt immediate consultation with an ophthalmologist.
In addition, nonneovascular AMD can transform to neovascular AMD, and neovascular AMD may transform into nonneovascular AMD. Both forms may be seen in the same eye or each eye may have a different form. It is not clear whether neovascular and nonneovascular AMD are different manifestations of the same disease or two different entities.
AMD is thought to be caused in part by exposure to ultraviolet radiation, mainly from sunlight. Just as skin can become damaged with excessive sun exposure, the pigmented layer of the retina that protects the photoreceptors can also become damaged with excessive UV light. Blue light was also found to induce damage.
Race and Ethnicity. Non-Hispanic whites in the U.S. have a 2.5% prevalence. In contrast, the U.S. black and Hispanic populations each have a prevalence of about 0.9%.
Age. AMD r arely occurs in persons under age 55. The prevalence is 0.8% in those aged 70 and older, increasing to 16% in those over 90.
Smoking. Individuals who smoke have a relative risk of 2.0 and greater, compared with those who have never smoked. Risk may remain elevated for 15 or more years after smoking cessation.
Family history. Genetic factors are linked to AMD and, combined with smoking, substantially increase risk.
Alcohol. Heavy use increases risk for early AMD.
Sunlight. AMD is believed to be more prevalent near the equator, but this has yet to be shown to be statistically significant.
The minimum age for diagnosis of AMD is 50 years. The classification system is based, not on visual acuity, but on characteristic findings on dilated retinal examination. These include changes in the retinal pigmented epithelium, periretinal hemorrhages, retinal atrophy, and retinal scarring. Drusen are not pathognomonic.
Ocular Coherence Tomography (OCT) is the gold standard in diagnosing and managing patients with neovascular AMD.
Slit-lamp photography of the macula is sometimes performed to document progression.
Fluorescein angiography detects the presence and location of any subretinal neovascularization, but its utilization has been lessened due to OCT.
Late stages of both neovascular and nonneovascular AMD can resemble other ophthalmologic diseases, which must be ruled out.
For prevention steps, see Nutritional Considerations, below.
Early AMD is typically managed by observation and lifestyle changes, especially avoidance of tobacco and alcohol. Patients should be referred to an ophthalmologist.
Vitamins C and E, beta-carotene, and zinc: Foods naturally high in these antioxidants have been shown to reduce progression from early to late disease (see Nutritional Considerations).
For intermediate to advanced disease, antioxidant supplements are indicated (See Nutritional Considerations, below). However, according to the Age-Related Macular Degeneration Preferred Practice Pattern 2015 guidelines, evidence does not support the use of these supplements for patients with less than intermediate AMD.
There is no specific medical or surgical treatment for nonneovascular AMD. Patients should be regularly monitored by an ophthalmologist and should report any abrupt changes in vision.
If OTC, or fluorescein angiography, reveals classic neovascularization, the first choice in treatment typically consists of intraocular injections of biologic agents, such as VEGF inhibitors. Aflibercept, ranibizumab, and bevacizumab (off-label use) are among the options for treatment. Thermal laser photocoagulation or photodynamic (laser) therapy are older options and ma y still be used in some cases. However, recurrences are common.
Photodynamic therapy (PDT), which is performed after intravenous injection of verteporfin that differentially enters neovascular tissue, offers limited benefit to patients with several forms of neovascular AMD. It does not restore vision, but rather is used to limit vision loss. Thanks to more effective medical therapy, this option is less commonly used.
Intravitreal steroid injections are under study and have achieved mixed results.
Submacular surgery is generally not recommended, and has not been shown to prevent vision loss at one year.
Macular translocation surgery has many complications, but could be a viable alternative for those who are not candidates for laser therapy. However, it remains unclear which patients, if any, are best served by this invasive approach. Long term studies are being conducted.
Dietary factors appear to play an important role in AMD. In epidemiologic studies, the following factors are associated with reduced risk of onset or progression of the disease:
Maintenance of ideal weight. Studies have found a higher risk for AMD in association with metabolic syndrome and measures of adiposity, including body mass index (BMI) and waist/hip ratio., ,
Low fat intake. Studies have found associations between high intakes of saturated fat and cholesterol and AMD. , Other studies have implicated vegetable fat and total fat intake in AMD. -, , People who regularly consumed processed baked goods had double the risk of AMD, compared with those who did not regularly consume these foods; the effect may relate to adverse effects on blood lipids or inflammation., However, the Age-Related Eye Disease Study 2 (AREDS2), a randomized, double-masked, placebo-controlled study found no protective benefit of DHA or EPA at five-year follow-up and a recent systematic review supported these findings. Genetics may influence the effect of fatty acids on AMD; more research is warranted. - 
High consumption of fruits and vegetables. Lutein and zeaxanthin are the principal carotenoids in the macular region of the retina. They are abundant in dark-green, leafy vegetables and appear to play an important role in prevention of macular degeneration. , Several studies have found that people with high intake of fruits and vegetables had a significantly lower risk for AMD compared with those who have low intakes. -  The Health Professionals Follow-Up Study and Nurses’ Health Study found an inverse association between fruit intake and risk for neovascular age-related maculopathy.
Antioxidant supplements. In the Age-Related Eye Disease Study, individuals with moderate or advanced AMD who received 500 mg of vitamin C, 400 IU of vitamin E, 15 mg of beta carotene, and 80 mg of zinc oxide (and 2 mg cupric oxide to prevent copper deficiency) had significantly reduced progression of their disease, compared with subjects receiving a placebo. Caution is advised, however, for several reasons: This evidence derives from a single study. Also, beta-carotene supplementation may increase lung cancer risk among smokers. Finally, daily doses of vitamin E exceeding 400 IU may increase cardiovascular and all-cause mortality.
In the lutein antioxidant supplementation trial (LAST), a 10-mg supplement of lutein taken daily, alone or with an antioxidant vitamin combination, increased macular pigment density and improved visual function when compared with a placebo. Lutein supplementation also improved visual performance (visual acuity and glare sensitivity) in other controlled trials. Due to a saturation of transport mechanisms for these carotenoids, some individuals do not achieve increases in macular pigment density, in spite of increases in blood levels of lutein and zeaxanthin following supplementation. Other individuals may not benefit if they are overweight, because lutein and zeaxanthin will be taken up by adipose tissue, rather than by the macula. An ophthalmologist should make patient-specific recommendations, because the age of the patient, disease severity, duration of treatment, and potential inhibitory effect of lutein supplementation on other carotenoids should be taken into account.
Emphasize fresh fruits and vegetables, particularly leafy greens, such as collard or turnip greens, kale, and spinach. Orange peppers, corn and squash are also good sources of lutein and zeaxanthin.
Consider the following supplements in consultation with an ophthalmologist: Vitamin C 500 mg, vitamin E 400 IU, beta-carotene 15 mg, zinc oxide 80 mg, and cupric oxide 2 mg daily.
Lutein, dosed per ophthalmologist recommendations.
What to Tell the Family
Appropriate medical care and self-care can slow the loss of vision due to AMD. It is helpful to encourage smoking cessation and a diet that is low in fat and cholesterol and high in fruits and vegetables. That means including at least 1 serving daily of a dark leafy green vegetable, such as spinach, kale, collards, or turnip greens, along with 3 servings of fresh fruit per day. This diet is also beneficial to family members, who may have a higher risk of AMD. Supplemental lutein and certain vitamins and minerals (C, E, beta-carotene, and zinc/copper oxide) may be beneficial, but their use should be supervised by an ophthalmologist. Low-vision aids (such as special lighting and magnifiers) are available through eye clinics.
- Jager RD, Mieler WF, Miller JW: Age-related macular degeneration. N Engl J Med 358:2606, 2008 [PMID:18550876]
- Caban-Martinez AJ et al: Age-related macular degeneration and smoking cessation advice by eye care providers: a pilot study. Prev Chronic Dis 8:, 2011 [PMID:22005640]
- de Jong PT: Age-related macular degeneration. N Engl J Med 355:1474, 2006 [PMID:17021323]
- Glickman RD: Ultraviolet phototoxicity to the retina. Eye Contact Lens 37:196, 2011 [PMID:21646980]
- Sui GY et al: Is sunlight exposure a risk factor for age-related macular degeneration? A systematic review and meta-analysis. Br J Ophthalmol 97:389, 2013 [PMID:23143904]Sui GY et al: Is sunlight exposure a risk factor for age-related macular degeneration? A systematic review and meta-analysis. Br J Ophthalmol 97:389, 2013 [PMID:23143904]
- Age-Related Macular Degeneration (AMD) Tables. National Eye Institute website. Available at: https://nei.nih.gov/eyedata/amd/tables . Accessed November 3, 2015.
- Weih LM et al: Age-specific causes of bilateral visual impairment. Arch Ophthalmol 118:264, 2000 [PMID:10676793]
- Myers CE et al: Cigarette smoking and the natural history of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 121:1949, 2014 [PMID:24953792]
- Chong EW et al: Alcohol consumption and the risk of age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol 145:707, 2008 [PMID:18242575]
- Fraser-Bell S et al: Cardiovascular risk factors and age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol 145:308, 2008 [PMID:18222193]
- Chong EW et al: Red meat and chicken consumption and its association with age-related macular degeneration. Am J Epidemiol 169:867, 2009 [PMID:19234096]
- Ersoy L et al: Nutritional risk factors for age-related macular degeneration. Biomed Res Int 2014:, 2014 [PMID:25101280]
- Vassilev ZP et al: Diabetes, cardiovascular morbidity, and risk of age-related macular degeneration in a primary care population. Invest Ophthalmol Vis Sci 56:1585, 2015 [PMID:25670489]
- Bird AC et al: An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39:367, 1995 Mar-Apr [PMID:7604360]
- Abdelsalam A, Del Priore L, Zarbin MA: Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol 44:1, 1999 Jul-Aug [PMID:10466585]
- Seddon JM et al: Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 121:785, 2003 [PMID:12796248]
- Knudtson MD, Klein R, Klein BE: Physical activity and the 15-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Br J Ophthalmol 90:1461, 2006 [PMID:17077116]
- Loprinzi PD, Swenor BK, Ramulu PY: Age-Related Macular Degeneration Is Associated with Less Physical Activity among US Adults: Cross-Sectional Study. PLoS ONE 10:, 2015 [PMID:25933421]
- Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119:1417, 2001 [PMID:11594942]Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119:1417, 2001 [PMID:11594942]
- Age-Related Macular Degeneration PPP - Updated 2015. American Academy of Ophthalmology website. Available at: http://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015 . Published January 2015. Accessed August 16, 2017.
- Lebuisson DA, Leroy L, Rigal G: [Treatment of senile macular degeneration with Ginkgo biloba extract. A preliminary double-blind drug vs. placebo study]. Presse Med 15:1556, 1986 [PMID:2947098]
- Fies P, Dienel A: [Ginkgo extract in impaired vision--treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration]. Wien Med Wochenschr 152:423, 2002 [PMID:12244891]
- Evans JR: Ginkgo biloba extract for age-related macular degeneration. Cochrane Database Syst Rev Jan 31 [PMID:23440785]
- Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 117:1329, 1999 [PMID:10532441]
- Gillies MC et al: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121:667, 2003 [PMID:12742844]
- Giansanti F, Eandi CM, Virgili G: Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration. Cochrane Database Syst Rev [PMID:19370663]
- Ghaem Maralani H et al: Metabolic syndrome and risk of age-related macular degeneration. Retina (Philadelphia, Pa) 35:459, 2015 [PMID:25207946]
- Zhang QY et al: Overweight, Obesity, and Risk of Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 57:1276, 2016 [PMID:26990164]
- Smith W et al: Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 116:583, 1998 [PMID:9596493]
- Smith W, Mitchell P, Leeder SR: Dietary fat and fish intake and age-related maculopathy. Arch Ophthalmol 118:401, 2000 [PMID:10721964]
- Mares-Perlman JA et al: Dietary fat and age-related maculopathy. Arch Ophthalmol 113:743, 1995 [PMID:7786215]
- Seddon JM, Cote J, Rosner B: Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 121:1728, 2003 [PMID:14662593]
- Cho E et al: Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr 73:209, 2001 [PMID:11157315]
- Seddon JM et al: Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol 119:1191, 2001 [PMID:11483088]
- Augood C et al: Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Am J Clin Nutr 88:398, 2008 [PMID:18689376]
- Age-Related Eye Disease Study 2 Research Group: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309:2005, 2013 [PMID:23644932]
- Lawrenson JG, Evans JR: Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 4:, 2015 [PMID:25856365]
- Merle BM et al: Adherence to a Mediterranean diet, genetic susceptibility, and progression to advanced macular degeneration: a prospective cohort study. Am J Clin Nutr 102:1196, 2015 [PMID:26490493]
- Souied EH et al: Omega-3 Fatty Acids and Age-Related Macular Degeneration. Ophthalmic Res 55:62, 2015 [PMID:26610051]
- Reynolds R, Rosner B, Seddon JM: Dietary omega-3 fatty acids, other fat intake, genetic susceptibility, and progression to incident geographic atrophy. Ophthalmology 120:1020, 2013 [PMID:23481534]
- Scripsema N, Hu D, Rosen R. Lutein, zeaxanthin, and meso-zeaxanthin in the clinical management of eye disease. J Ophthalmol . 2015;2015:1-13.
- Bernstein PS et al: Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Prog Retin Eye Res 50:34, 2016 [PMID:26541886]
- Wu J et al: Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related Macular Degeneration During 2 Decades of Prospective Follow-up. JAMA Ophthalmol 133:1415, 2015 [PMID:26447482]
- Zeimer M et al: [The macular pigment: short- and intermediate-term changes of macular pigment optical density following supplementation with lutein and zeaxanthin and co-antioxidants. The LUNA Study]. Ophthalmologe 106:29, 2009 [PMID:18551295]
- Tan JS et al: Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 115:334, 2008 [PMID:17664009]
- Cho E et al: Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 122:883, 2004 [PMID:15197064]
- Miller ER et al: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:37, 2005 [PMID:15537682]
- Richer S et al: Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 75:216, 2004 [PMID:15117055]
- Olmedilla B et al: Lutein, but not alpha-tocopherol, supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind, placebo-controlled pilot study. Nutrition 19:21, 2003 [PMID:12507634]
- Trieschmann M et al: Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res 84:718, 2007 [PMID:17306793]
- Hammond BR, Ciulla TA, Snodderly DM: Macular pigment density is reduced in obese subjects. Invest Ophthalmol Vis Sci 43:47, 2002 [PMID:11773011]